Key Drivers
- Strong liquidity
- Persistent losses
- Cash burn
AIAI Summary
CAPR has shifted from a speculative biotech to a near-term binary FDA catalyst with credible Phase 3 data and a firm Aug. 22, 2026 PDUFA, but after the stock's rerating the trade now hinges on approval and launch execution—any delay, regulatory pushback, or commercialization miss could trigger a sharp reset despite ample cash runway.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •Cash burn
CAPR has a very strong cash-rich balance sheet and low debt, but persistent no-revenue losses, negative cash flow, and erosion of book value make the stock fundamentally challenged despite ample near-term liquidity.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Failed rebound
- •Near support
Over the last month, CAPR has rolled over from an uptrend into a lower-high/lower-low pullback, failing at the $31 pivot and now testing support near $28.8–$29.0, so momentum remains fragile unless it reclaims $31.
Sharp drop from the 2026-04-21 peak into near-range lows suggests oversold risk
Sentiment & News
Key News Insights:
- •Phase 3 Win
- •FDA On Track
- •Legal Overhang
Capricor's deramiocel posted strong Phase 3 results and remains on track for FDA action by 2026-08-22, but the Nippon Shinyaku/NS Pharma dispute and distribution concerns create a near-term overhang.
The news is modestly positive for approval prospects, but litigation and commercialization uncertainties may keep the stock volatile until the PDUFA date
Similar Companies in Healthcare
Other companies in the same sector with AI ratings